Business Wire

Seoul Semiconductor and Toshiba Materials Taking LEDs Back to Nature

28.6.2017 07:07 | Business Wire

Del

Combining Seoul Semiconductor’s patented LED chip technology & Toshiba Materials’ TRI-R phosphor technology, SunLike Series LEDs deliver the world’s best light quality in a next-generation LED that enables human-centric lighting optimized for circadian rhythms

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170628005183/en/

Chung Hoon Lee, Founder and CEO of Seoul Semiconductor Co., Ltd. (Photo: Business Wire)

Chung Hoon Lee, Founder and CEO of Seoul Semiconductor Co., Ltd. (Photo: Business Wire)

Seoul Semiconductor, a global innovator of LED products and technology, has developed a new LED technology that produces light that closely matches the spectrum of natural sunlight. Announced at a press conference in Frankfurt, Germany on June 26, 2017, the new SunLike Series natural spectrum LED technology was co-developed by Seoul Semiconductor and Toshiba Materials.

Back to natural light

Human beings have lived under natural sunlight for tens of thousands of years, and only began using lanterns in the third century BCE. The use of white LEDs for general illumination began less than 20 years ago, but has spread rapidly around the world due to the high efficiency and cost savings of LED lighting. However, low cost and brightness has been given priority over the quality of light, thus the light from conventional LEDs has a different characteristic from that of natural sunlight, which matches the human biorhythm.

The SunLike Series LED technology closely matches the spectrum of natural sunlight that human have enjoyed for thousands of years. It maximizes the advantage of natural light and minimizes the shortcomings of artificial light sources, providing light more like natural sunlight. This natural spectrum of light is achieved by combining Seoul Semiconductor’s world-class LED chip technology with Toshiba Materials’ TRI-R technology, a leading global phosphor compound.

“Mr. Kumpei Kobayashi, CEO of Toshiba Materials said that “We are pleased to be partnered with a global LED leader like Seoul Semiconductor to introduce the SunLike Series natural spectrum LEDs, which represent an advanced technology that creates a more intimate and nature-based lighting environment.”

“We are pleased to introduce another South Korean innovation in LED technology with the launch of the SunLike Series LED lighting technology that produces light close to the spectrum of natural sunlight. Much like our package-less WICOP Series LEDs revolutionized the LED packaging process, our SunLike Series LEDs represents a revolution in creating natural spectrum LED lighting.” said Mr. Chung Hoon Lee, CEO of Seoul Semiconductor. “The SunLike Series LEDs will be applied in the lighting sector, contributing to a better and healthier life for humans. They will also be used in horticultural applications to create an ideal environment to help plants grow which is safer than using genetic modification,” he added.

He also said “We are delighted to partner with Toshiba Materials to provide our customers a light source that delivers the natural spectrum of sunlight – from the brightness of morning sunshine, to the energy of daylight, to the warmth of an evening sunset. We believe that the SunLike Series LEDs will improve the quality of human life by advancing a new era of human-centric lighting technology.”

Minimizing the side-effects of blue light

Because SunLike Series LEDs are designed to deliver light that closely matches the natural spectrum of sunlight, they provide an optimized light source for human centric lighting that maximizes benefits of natural light while minimizing the negative side effects of artificial light sources.

Some recent studies from Harvard1 and other major universities have suggested that blue LED chips, used in most commercial LEDs to create visible light, provide positive stimulation to the human eye that increases alertness and elevates mood when viewed during daytime hours. However, these blue LEDs create a blue light “spike” in the light output of an LED that may produce negative effects when viewed for prolonged periods during night-time hours by interfering with natural human biorhythms. The SunLike Series natural spectrum LED technology employs a purple LED in conjunction with the TRI-R phosphor compound to minimize the blue light “spike” that is characteristic of typical LED light sources, producing a light output that closely matches the spectrum of natural sunlight to deliver a healthier light experience.

SunLike’s world-class color reproduction

According to the results of published research in academic journals such as Nature2, because humans have lived under the sun for thousands of years, human organs and biorhythms have evolved to respond most appropriately to natural sunlight. Human retinal cells that interpret and respond to color-related light input are composed of red, blue, and green cones, and the percentage of blue receptors was only 5.7%.

Because the amount of blue light that our eyes can accept is limited, blue light above the limit entering the eye is scattered. When this scattering phenomenon occurs, the light is diffused, and as a result, the texture and color of objects are distorted. Also, excess blue light can over-stimulate these retinal cells in the eye, and may cause eyestrain and loss of concentration. However, since SunLike Series LEDs implement the spectrum closest to the sunlight, they more accurately represent the color and texture of the object in natural light without the negative effects of excessive blue light on the eye or human biorhythms. Several products in which Toshiba’s TRI-R technology were incorporated have already been applied to lighting in Milan Fashion Week and illuminating fine art paintings in museum settings.

Applications and Market Forecast

SunLike will primarily be applied in commercial facilities that need to distinguish or show the exact color of the product as seen under sunlight, such as department stores, fine jewelers, horticulture facilities for growing plants indoors, exhibition facilities such as museums and exhibition halls, cosmetic facilities such as dressing rooms or bathrooms.

The global lighting market is estimated at $87 billion, with LED lighting accounting for ~$35 billion. The overall segment of the LED market where the SunLike Series LEDs can be applied represents ~$17 billion. It is anticipated that the SunLike Series natural spectrum LEDs will find initial sales in applications that require high quality lighting, and will eventually be applied in the general lighting market.

The SunLike Series natural spectrum LEDs are available from Seoul Semiconductor. To learn more about the SunLike Series natural spectrum LEDs, please visit: http://www.seoulsemicon.com/en/technology/Sunlike/

For more information about Seoul Semiconductor, please visit http://www.seoulsemicon.com

1 Blue Light Articles (Source: Harvard Medical School)

http://www.health.harvard.edu/staying-healthy/blue-light-has-a-dark-side

2Source: http://www.nature.com/nature/journal/v397/n6719/full/397520a0.html

*Nature paper number: Roorda et al. Nature, 397, 520-522, (1999)

About Seoul Semiconductor:

Seoul Semiconductor develops and commercializes light emitting diodes (LEDs) for automotive, general illumination, specialty lighting, and backlighting markets. As the fourth-largest LED manufacturer globally, Seoul Semiconductor holds more than 12,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as Wicop – a simpler structured package-free LED which provides market leading color uniformity, cost savings at the fixture level with high lumen density and allows design flexibility; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, includes all AC LED-related technologies from chip to module and circuit fabrication, as well as multi-junction technology (MJT); and nPola, a new LED product based on GaN-substrate technology that achieves over ten times the output of conventional LEDs. For more information about Seoul Semiconductor, please visit http://www.seoulsemicon.com.

About Toshiba Materials

Toshiba Materials Co., Ltd. (http://www.toshiba-tmat.co.jp/eng/) was demerged from Toshiba Corporation in 2003. With material design technology as a core, Toshiba Materials has supplied key material and key components which support the development of society.

Main products are metallic materials, components, fine ceramics parts, and chemical materials. During the year ended March 31, 2017, the company’s net sales totaled ~$127MM (14 billion yen).

# Trademarks

Wicop and Acrich are trademarks of Seoul Semiconductor Co., Ltd.

TRI-R is trademark of Toshiba Materials Co.

Contact information

Seoul Semiconductor GmbH
Europe
Ariane Heim
Tel: +49 (0)89 450 3690-0
Email: press.eu@seoulsemicon.com
or
North America
Seoul Semiconductor Inc.
David Cox
Tel: +1 (919) 410-9856
Email: David.cox@seoulsemicon.com
or
Asia
Seoul Semiconductor Co., Ltd
Jake Jung
Tel: +82 070.4391.8270
Email: pr@seoulsemicon.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

XILAM Successfully Completes €15m Bond Issue on Euro PP Market27.7.2017 17:42Pressemelding

Regulatory News: Xilam (Paris:XIL) today announced the completion of its Euro PP bond issue. The €15 million private placement, repayable at maturity, was subscribed by the NOVI 2 fund managed by Idinvest Partners on behalf of institutional investors and by a European insurer. The bonds have a 6-year maturity, and will be issued in two tranches: The first tranche will be at a variable rate of 6-month EURIBOR* + 400 bp The second tranche will be at a fixed rate of 3.5%. Favourable terms were obtained for the issue with successive drawdown options (limited to 18 months), which will allow the company to optimise the cost of its debt according to its needs. Xilam was advised on the transaction by Euroland Corporate. “We are delighted to have successfully completed this financing transacti

SFL – First-Half 2017 Results27.7.2017 17:00Pressemelding

Regulatory News: The interim consolidated financial statements for the six months ended 30 June 2017 were approved by the Board of Directors of Société Foncière Lyonnaise (Paris:FLY) on 27 July 2017, at a meeting chaired by Juan-Jose Brugera. First-half business indicators were robust, thanks to the high portfolio occupancy rate, while the period also saw gains in the portfolio's appraisal value and the Company's net asset value. The auditors have completed their review of the interim financial statements. Consolidated data (€ millions)                

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®27.7.2017 13:00Pressemelding

Boehringer Ingelheim announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study. The goal of the study is to demonstrate that BI 695501 is interchangeable with the U.S.-marketed formulation of Humira®* 40mg/0.8mL. This is the first study in the U.S. to investigate an interchangeability designation for an adalimumab biosimilar candidate. The study will compare the pharmacokinetics and clinical outcomes between patients receiving Humira® continuously, versus those who switch repeatedly between Humira® and BI 695501, Boehringer Ingelheim’s adalimumab biosimilar candidate.1 The study will also assess safety, immunogenicity and efficacy.1 “We are pleased that the first patient has now been enrolled in VOLTAIRE-X, and look forward to continued recruitment and patient follow-up,” said Ivan Blanarik, Senior Vice President and Head of

Acxiom Launches Connected Spaces27.7.2017 12:30Pressemelding

Today, Acxiom® (Nasdaq: ACXM), in collaboration with Adobe, announced the launch of Connected Spaces, a global solution aimed at delivering more relevant omnichannel experiences to customers. Connected Spaces is designed to revolutionise customer experience and business returns for retail, travel and leisure locations such as airports, malls, sports stadiums, concert arenas and resorts. A pioneering example is Heathrow airport. Heathrow is able to deliver more relevant communications to customers in real-time as part of its overall engagement strategy and is already generating exceptional results including an increase in spend of 20-25 percent for engaged customers. Common to airports, malls and the like is a high footfall of consumers who intend to visit multiple concession, franchise, or subcontracted brands operating in their environments. This can translate to a relative

Watch BizWireTV: Helix Brings DNA Kits to the Public and Michael Kors Gets Ready to Buy Jimmy Choo27.7.2017 12:08Pressemelding

On the latest BizWireTV, catch the latest Quick Biz Hits. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170727005456/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire) Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Helix launches first online consumer marketplace for DNA-powered products that offer insights on ancestry, entertainment, family, fitness, health and nutrition. Watch BizWireTV to

European Commission Grants Orphan Drug Designation to Allena Pharmaceuticals’ Investigational Therapy for the Treatment of Primary Hyperoxaluria27.7.2017 11:05Pressemelding

Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company dedicated to bringing first in class, specific, non-absorbed, oral enzyme therapeutics to patients with serious renal, urologic and orphan diseases, announced today that the European Commission has granted orphan drug designation to Allena’s investigational product ALLN-177, Bacillus subtilis oxalate decarboxylase, for the treatment of primary hyperoxaluria (PH). The orphan designation was granted to Allena Pharmaceuticals Ireland Limited, a subsidiary of Allena Pharmaceuticals, Inc. Allena’s lead compound ALLN-177, is being developed to treat patients with severe hyperoxaluria, a condition characterized by markedly elevated urinary oxalate excretion. PH, a type of severe hyperoxaluria, is a rare genetic disorder caused by endogenous overproduction of oxalate by the liver that can result in kidney stone disease, kidney

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom